Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.
Cejalvo JM, Jacob W, Fleitas Kanonnikoff T, Felip E, Navarro Mendivil A, Martinez Garcia M, Taus Garcia A, Leighl N, Lassen U, Mau-Soerensen M, Adessi C, Michielin F, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A. Cejalvo JM, et al. ESMO Open. 2019 Jul 22;4(4):e000532. doi: 10.1136/esmoopen-2019-000532. eCollection 2019. ESMO Open. 2019. PMID: 31423336 Free PMC article.
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A. Schneeweiss A, et al. Among authors: cejalvo jm. Invest New Drugs. 2018 Oct;36(5):848-859. doi: 10.1007/s10637-018-0562-4. Epub 2018 Jan 19. Invest New Drugs. 2018. PMID: 29349598 Free PMC article. Clinical Trial.
In the literature: April 2019.
Bruxiola G, Cejalvo JM, Gambardella V, Cervantes A. Bruxiola G, et al. Among authors: cejalvo jm. ESMO Open. 2019 Apr 20;4(2):e000513. doi: 10.1136/esmoopen-2019-000513. eCollection 2019. ESMO Open. 2019. PMID: 31231563 Free PMC article. No abstract available.
In the literature: June 2019.
Lamarca A, Gambardella V, Cejalvo JM, Fleitas-Kanonnikoff T, Cervantes A. Lamarca A, et al. Among authors: cejalvo jm. ESMO Open. 2019 Jun 20;4(3):e000547. doi: 10.1136/esmoopen-2019-000547. eCollection 2019. ESMO Open. 2019. PMID: 31297241 Free PMC article. No abstract available.
In the literature: August 2018.
Gambardella V, Bruixola G, Papaccio F, Cejalvo JM, Cervantes A. Gambardella V, et al. Among authors: cejalvo jm. ESMO Open. 2019 Jul 21;4(4):e000563. doi: 10.1136/esmoopen-2019-000563. eCollection 2019. ESMO Open. 2019. PMID: 31423340 Free PMC article. No abstract available.
In the literature: December 2019.
Gambardella V, Insa A, Cejalvo JM, Cervantes A. Gambardella V, et al. Among authors: cejalvo jm. ESMO Open. 2020 Jan;5(1):e000642. doi: 10.1136/esmoopen-2019-000642. ESMO Open. 2020. PMID: 31958287 Free PMC article. No abstract available.
In the literature: February 2020.
Roda D, Gambardella V, Cejalvo JM, Cervantes A. Roda D, et al. Among authors: cejalvo jm. ESMO Open. 2020 Feb;5(1):e000680. doi: 10.1136/esmoopen-2020-000680. ESMO Open. 2020. PMID: 32079625 Free PMC article. No abstract available.
69 results